JP2002097153A - Composition containing glutathione-containing yeast extract - Google Patents
Composition containing glutathione-containing yeast extractInfo
- Publication number
- JP2002097153A JP2002097153A JP2000283502A JP2000283502A JP2002097153A JP 2002097153 A JP2002097153 A JP 2002097153A JP 2000283502 A JP2000283502 A JP 2000283502A JP 2000283502 A JP2000283502 A JP 2000283502A JP 2002097153 A JP2002097153 A JP 2002097153A
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- yeast extract
- coating
- solidified product
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 64
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 32
- 229960003180 glutathione Drugs 0.000 title claims abstract description 32
- 229940041514 candida albicans extract Drugs 0.000 title claims abstract description 29
- 239000012138 yeast extract Substances 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000011248 coating agent Substances 0.000 claims abstract description 49
- 238000000576 coating method Methods 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000000748 compression moulding Methods 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000004090 dissolution Methods 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000454 talc Substances 0.000 claims description 14
- 229910052623 talc Inorganic materials 0.000 claims description 14
- 229920001800 Shellac Polymers 0.000 claims description 12
- 239000004208 shellac Substances 0.000 claims description 12
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 12
- 235000013874 shellac Nutrition 0.000 claims description 12
- 229940113147 shellac Drugs 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 6
- -1 and hemylose Substances 0.000 claims description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 241000237502 Ostreidae Species 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 235000020636 oyster Nutrition 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 6
- 239000000284 extract Substances 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- 230000000873 masking effect Effects 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 23
- 210000000214 mouth Anatomy 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- 235000008429 bread Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000005002 finish coating Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000006364 Torula Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011802 pulverized particle Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、グルタチオンを含
有する酵母エキス成分の不快な味や臭いをマスクし、該
エキス成分を、口中で溶解させて服用するとを可能とし
た組成物を提供する。TECHNICAL FIELD The present invention provides a composition which masks the unpleasant taste and odor of a yeast extract component containing glutathione, and allows the extract component to be dissolved in the mouth and taken.
【0002】[0002]
【従来の技術】医療用、医薬品原料としてのグルタチオ
ンは、免疫力を増強し、以前より肝機能障害改善の治療
薬として利用されてきた。グルタチオンの薬効は幅広い
ものが知られており、例えば脂肪、タンパク質、糖の代
謝を活発にすると共に、解毒、肝機能改善、脂肪肝改
善、抗アレルギーなどの作用を示す。グルタチオンは様
々な症状や疾患の治療および予防に用いられており、例
えば薬物中毒、アセトン結性嘔吐症(時下中毒、周期性
嘔吐症)、金属中毒、妊娠嘔吐、霧視などへ処方されて
いる。2. Description of the Related Art Glutathione as a medical or pharmaceutical raw material has been used as a therapeutic agent for enhancing immunity and improving liver dysfunction for a long time. Glutathione is known to have a wide range of medicinal effects. For example, it activates the metabolism of fat, protein, and sugar, and exhibits effects such as detoxification, liver function improvement, fatty liver improvement, and antiallergy. Glutathione is used for the treatment and prevention of various conditions and diseases, such as drug poisoning, acetone-induced vomiting (periodic poisoning, periodic vomiting), metal poisoning, pregnancy vomiting, and blurred vision. I have.
【0003】グルタチオンは動植物組織や微生物に広く
分布することが知られているが、一般にグルタチオン製
剤としては、酵母を原料として製造されている。近年、
精製前の高濃度酵母を、健康食品として取り扱うことが
可能となった。しかしながら、グルタチオン産生酵母菌
体やそのエキスは不快な臭いや味を有し、そのままでは
口にすることが不可能である。[0003] Glutathione is known to be widely distributed in animal and plant tissues and microorganisms. Generally, glutathione preparations are produced from yeast. recent years,
High-concentration yeast before purification can be handled as health food. However, glutathione-producing yeast cells and extracts thereof have an unpleasant odor and taste and cannot be eaten as it is.
【0004】特に、濃縮酵母エキスはグルタチオン含有
量が高く、薬理的効果としては高いものが期待される
が、悪臭がひどく、またひどく不味いため、経口摂取の
ためには、口腔内で溶け出さないようにした内服剤とす
るしかなかった。In particular, concentrated yeast extract has a high glutathione content and is expected to have a high pharmacological effect. However, since it has a bad odor and is extremely unpleasant, it does not dissolve in the oral cavity for oral ingestion. There was no choice but to use the internal medicine as described above.
【0005】内服剤やドリンク剤の場合は腸壁にて吸収
されるため、血中濃度上昇までの時間がかかる。一方、
例えばアルコール飲用による中毒症状の改善、即ち悪酔
い、二日酔い、肝機能障害等、服用後、迅速に作用する
ことが望まれる場合には、摂取から吸収時間を短くする
ことが必要である。そためには、口中で徐々に溶解また
は崩壊させて、舌下で吸収されるトローチやチュアブル
タイプといわれる製剤とすることが望まれる。[0005] In the case of oral preparations and drinks, it takes time for the blood concentration to rise because it is absorbed by the intestinal wall. on the other hand,
For example, when it is desired to act quickly after taking the drug, for example, to improve the symptoms of intoxication caused by drinking alcohol, ie, to get sick, hangover, or impaired liver function, it is necessary to shorten the absorption time from ingestion. For this purpose, it is desirable to gradually dissolve or disintegrate in the mouth to prepare a preparation called a troche or chewable type which is absorbed under the tongue.
【0006】[0006]
【発明が解決しようとする課題】本発明は、グルタチオ
ン含有酵母エキスが有する不快な臭いおよび味をマスク
し、口中で溶解させて服用し得る組成物として提供する
ことを目的とする。An object of the present invention is to provide a composition which masks the unpleasant odor and taste of the glutathione-containing yeast extract and which can be dissolved and taken in the mouth.
【0007】[0007]
【課題を解決するための手段】グルタチオンを含有する
酵母エキス粉末を無水条件下で圧縮成形により固形化物
を得る工程、得られた固形化物を破砕、造粒する工程、
破砕により得られた粒子を、コーティング剤で被覆する
工程、を含む、グルタチオン含有酵母エキスを含む組成
物の製造方法を提供する。A step of obtaining a solidified product by compressing and molding a yeast extract powder containing glutathione under anhydrous conditions; a step of crushing and granulating the obtained solidified product;
A method for producing a composition containing a glutathione-containing yeast extract, comprising a step of coating particles obtained by crushing with a coating agent.
【0008】本発明の方法において、圧縮成形により得
られる固形化物の硬度を10kg以上とし、これを破砕
して得られる粒子の平均粒径を、24〜80メッシュの
間とすることが好ましい。In the method of the present invention, the hardness of the solidified product obtained by compression molding is preferably 10 kg or more, and the average particle size of the particles obtained by crushing the solidified product is preferably between 24 and 80 mesh.
【0009】一旦圧縮した後に破砕、分級して得られる
粒子を次いで非水性コーティング剤により被覆する。[0009] The particles obtained by compression, crushing and classification are then coated with a non-aqueous coating agent.
【0010】非水性コーティング剤の被覆により得られ
た本発明の組成物は、賦形剤およびその他の添加剤と共
に適当な形状へと圧縮成形して、口中で徐々に溶解させ
て服用する、いわゆるチュアブル錠、トローチ錠などと
して提供される。本発明の口中で溶解させて服用するこ
とのできる組成物は、服用後、舌下から吸収されるため
迅速に作用し、特にアルコールの多量摂取による障害
等、急速な作用が望まれる場合に好適に用いられる。The composition of the present invention obtained by coating with a non-aqueous coating agent is compression-molded into an appropriate shape together with excipients and other additives, and is gradually dissolved in the mouth to be taken. It is provided as chewable tablets, troches and the like. The composition of the present invention which can be taken by dissolving in the mouth can be taken quickly after the ingestion because it is absorbed from under the tongue, and is particularly suitable when a rapid action such as a disorder due to a large intake of alcohol is desired. Used for
【0011】[0011]
【発明の実施の形態】本発明に用いられるグルタチオン
を含む酵母エキスは、パン酵母、アルコール発酵酵母な
どを公知の手法で培養して得られる菌体から公知の方法
で抽出して得られる。BEST MODE FOR CARRYING OUT THE INVENTION The yeast extract containing glutathione used in the present invention is obtained by a known method from cells obtained by culturing baker's yeast, alcohol-fermenting yeast and the like by a known method.
【0012】本発明に用いる酵母エキス粉末は、得られ
た抽出物を濃縮し、賦型剤を加え、乾燥することにより
粉末製品としたものである。賦形剤としては、例えばデ
キストリン、ゼラチン、カゼインナトリウム、ラクトア
ルブミンおよび卵白などが例示される。[0012] The yeast extract powder used in the present invention is obtained by concentrating the obtained extract, adding an excipient, and drying to obtain a powder product. Examples of the excipient include dextrin, gelatin, sodium caseinate, lactalbumin and egg white.
【0013】酵母エキス粉末としては市販のものが容易
に入手できる。酵母エキス粉末はグルタチオンを8〜1
0%含有している物を用いるのが好ましい。市販の酵母
エキス粉末、例えばグルタチオン含量8%のトルラ酵母
エキスが特に好適に用いられる。[0013] Commercially available yeast extract powder is readily available. The yeast extract powder contains glutathione 8 to 1
It is preferable to use a substance containing 0%. Commercially available yeast extract powders, for example, Torula yeast extract having a glutathione content of 8% are particularly preferably used.
【0014】本発明の方法においては、酵母エキス粉末
を適当な型で圧縮成形する。成形は、通常医薬品や栄養
補助食品の錠剤を製造する場合に用いられる打錠装置を
用いて行えばよい。成形にあたっては、材料が杵に付着
することを防止するため製剤の際に通常用いられる滑沢
剤、例えばショ糖脂肪酸エステルを添加することが好ま
しいIn the method of the present invention, the yeast extract powder is compression-molded in an appropriate mold. The molding may be carried out using a tableting device usually used for producing tablets of medicines and dietary supplements. In molding, it is preferable to add a lubricant usually used in the preparation, for example, a sucrose fatty acid ester in order to prevent the material from adhering to the punch.
【0015】圧縮成形工程により得られる固形化物は、
好ましくは硬度10kg以上、より好ましくは14kg
以上の錠剤とする。硬度の上限は特に無いが、17.5
kg以上の硬度であってもよい。The solidified product obtained by the compression molding step is
Preferably hardness 10 kg or more, more preferably 14 kg
The above tablets are used. There is no particular upper limit for the hardness, but 17.5.
The hardness may be not less than kg.
【0016】成形時の圧力は、所望の硬度を得ることが
できる圧力であればよく、特に限定的ではないが、15
00kg/cm2以上、特に1700kg/cm2以上で
あることが好ましい。成形時の圧力の上限は特になく、
例えば3000kg/cm2以上の圧力で打錠してもよ
い。The pressure at the time of molding is not particularly limited as long as a desired hardness can be obtained.
00kg / cm 2 or more, and particularly preferably 1700 kg / cm 2 or more. There is no particular upper limit for the pressure during molding,
For example, tableting may be performed at a pressure of 3000 kg / cm 2 or more.
【0017】所望の硬度とした固形化物を次いで破砕す
る。破砕は、医薬品の製造の際に通常用いられている装
置を用いて行えばよい。破砕して得た粒子を分級し、2
0〜90メッシュ、好ましくは24〜80メッシュの粒
子径のものを得る。The solidified product having the desired hardness is then crushed. The crushing may be performed using a device usually used in the production of a pharmaceutical. Classify the particles obtained by crushing,
Particles having a particle size of 0 to 90 mesh, preferably 24 to 80 mesh are obtained.
【0018】得られた粒子を、次いで非水性コーティン
グ剤で被覆する。被覆は、アルコール溶解性物質を、ア
ルコール溶液としたものによりまず被覆し、次いで粉末
コーティング剤でさらに被覆するとよい。被覆は、通常
医薬品や栄養補助食品の製造の際に顆粒等の被覆に用い
られている装置のいずれかを用いて行えば良い。例えば
糖衣パンを用いる場合、固形化物を粉砕、分級して得た
粒子を糖衣パン中へ投入し、ここへコーティング剤のア
ルコール溶液を噴霧して被覆処理した後、粉末コーティ
ング剤を投入してさらに処理すればよい。The particles obtained are then coated with a non-aqueous coating. The coating may be performed by first coating the alcohol-soluble substance with an alcohol solution, and then further coating with a powder coating agent. Coating may be carried out using any of the devices usually used for coating granules and the like in the production of pharmaceuticals and dietary supplements. For example, when a sugar-coated bread is used, the solidified product is pulverized, the particles obtained by classification are put into a sugar-coated bread, and an alcohol solution of a coating agent is sprayed thereon to perform a coating treatment. It should be processed.
【0019】アルコール溶解性の非水性コーティング剤
としては、通常医薬品や栄養補助食品の製造において採
用される物資をいずれも好適に採用することができ例え
ば、シェラック、ヒドロキシエチルセルロース、ヒドロ
キシプロピルスターチ、ヒドロキシプロピルセルロー
ス、ヘミロースなどが例示される。As the alcohol-soluble non-aqueous coating agent, any of the materials usually used in the manufacture of pharmaceuticals and dietary supplements can be suitably used. For example, shellac, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl Cellulose, hemylose and the like are exemplified.
【0020】アルコール溶解性物質による被覆の後、さ
らにタルク、牡蠣殻を含むボレイ、酸化亜鉛、酸化アル
ミニウム、酸化カルシウム、酸化チタン、酸化プロピレ
ン、酸化マグネシウム、炭酸カリウム、炭酸カルシウ
ム、炭酸水素ナトリウム、炭酸ナトリウム、炭酸マグネ
シウム、炭酸リチウム、沈降炭酸カルシウムおよび天然
ケイ酸アルミニウムからなる群から選択される、粉末状
のコーティング剤を適用する。かかる粉末状コーティン
グ剤を適用することによって、上記アルコール溶解性物
質による被覆のみではべたついてしまう粒子が、べたつ
かなくなり、酵母エキスの味、および臭いのマスキング
効果がさらに上昇する。After coating with an alcohol-soluble substance, talc, boray including oyster shells, zinc oxide, aluminum oxide, calcium oxide, titanium oxide, propylene oxide, magnesium oxide, potassium carbonate, calcium carbonate, sodium hydrogen carbonate, carbonate A coating in powder form, selected from the group consisting of sodium, magnesium carbonate, lithium carbonate, precipitated calcium carbonate and natural aluminum silicate is applied. By applying such a powdery coating agent, particles that become sticky only by coating with the alcohol-soluble substance are not sticky, and the taste and smell masking effects of the yeast extract are further increased.
【0021】粉末状コーティング剤による被覆が終了し
た後、乾燥する。なお、上記非水性コーティング剤によ
る被覆は、1回のみ行っても、アルコール溶解性物質に
よる被覆―粉末状物質による被覆―乾燥の工程を2回以
上繰り返して行ってもよい。好ましくは、被覆工程を2
回以上繰り返し、複数の被覆層を形成させ、味および臭
いのマスキング効果を高めることである。なお、乾燥工
程においては、温度を50℃未満、好ましくは40℃未
満とする。温度が50℃を超えると、グルタチオンが分
解して劣化する。After the coating with the powdery coating agent is completed, it is dried. The coating with the non-aqueous coating agent may be performed only once, or the coating with an alcohol-soluble substance, the coating with a powdery substance, and the drying may be repeated twice or more. Preferably, the coating step is 2
That is, to form a plurality of coating layers by repeating the coating more than once, thereby enhancing the taste and smell masking effect. In the drying step, the temperature is lower than 50 ° C, preferably lower than 40 ° C. If the temperature exceeds 50 ° C., glutathione is decomposed and deteriorated.
【0022】コーティング剤の被覆量は、コーティング
剤の種類により適宜選択すればよい。例えばひとつの態
様において、精製シェラックのアルコール溶液およびタ
ルクを非水性コーティング剤として用い、下地被覆と仕
上げ被覆の2段階で被覆する場合、最初の下地被覆にお
いて、精製シェラックを0.5g/ml含有するエタノ
ール溶液を粉砕粒子の約26重量%を噴霧して被覆した
後、べたついた表面をタルクで処理する。タルクの量は
限定的ではないが破砕粒子重量の約24〜25重量%と
すればよい。下地被覆終了後、粒子を一旦乾燥させて、
仕上げ被覆を行う。仕上げ被覆において同濃度のエタノ
ール溶液を、粉砕粒子の約7重量%用いて被覆し、さら
に6〜7重量%のタルクで処理すると、好ましい組成物
が得られる。The coating amount of the coating agent may be appropriately selected depending on the type of the coating agent. For example, in one embodiment, when an alcoholic solution of purified shellac and talc are used as the non-aqueous coating agent and are coated in two stages, a base coat and a finish coat, the first base coat contains 0.5 g / ml purified shellac. After coating the ethanol solution by spraying about 26% by weight of the ground particles, the sticky surface is treated with talc. The amount of talc is not limited, but may be about 24 to 25% by weight of the crushed particles. After completion of the undercoat, the particles are dried once,
Finish coating is applied. The preferred composition is obtained by coating the same concentration of ethanol solution in the finish coat with about 7% by weight of the ground particles and further treating with 6-7% by weight of talc.
【0023】本発明によって得られる被覆粒子は、グル
タチオン含有酵母エキスの不快な味や臭いが十分マスク
されており口中で溶解または崩壊させながら服用するこ
とが可能である。被覆粒子は、必要に応じて分級し、さ
らに加工しても、そのまま服用させてもよい。The coated particles obtained according to the present invention are sufficiently masked for the unpleasant taste and odor of the glutathione-containing yeast extract and can be taken while dissolving or disintegrating in the mouth. The coated particles may be classified as needed, further processed, or taken as is.
【0024】こうして得られる本発明の組成物は、グル
タチオン含有粒子として栄養補助食品や医薬品へ用いる
ことができる。顆粒剤としてそのまま経口投与しても、
また他の成分を含む経口投与用製剤中や、食品中へ添加
してもよい。The composition of the present invention thus obtained can be used as a glutathione-containing particle for nutritional supplements and pharmaceuticals. Even if it is orally administered as a granule,
Further, it may be added to a preparation for oral administration containing other components or a food.
【0025】本発明の方法により得られる被覆粒子をさ
らに、適当な賦形剤およびその他の添加剤と共に圧縮成
形し、口中で溶解させて服用するための錠剤を製造して
もよい。かかる口中で溶解させながら成分を吸収するた
めの組成物もまた、本発明の範囲に含まれる。The coated particles obtained by the method of the present invention may be further subjected to compression molding together with appropriate excipients and other additives to produce a tablet to be dissolved in the mouth and taken. Such compositions for absorbing components while dissolving in the mouth are also included in the scope of the present invention.
【0026】口中で溶解させて服用するための組成物を
製造する際、本発明により得られた被覆粒子に添加する
賦形剤およびその他の添加剤としては、通常栄養補助食
品や医薬品の分野で、口中で溶解させるトローチ剤やチ
ュアブル剤等を製造する際に用いることが知られている
公知のものを適宜用いればよい。添加剤としては非水性
の結合剤、崩壊剤、甘味料、香料、保存料などが例示さ
れる。口中で溶解させる組成物の製造は、従来から知ら
れている、トローチ剤やチュアブル剤の製造方法に順じ
て行えばよい。簡単には、賦形剤およびその他の添加剤
を本発明の被覆粒子と混合し、適当な打錠装置により打
錠すればよい。錠剤の形状や物理的性質等は特に限定さ
れず、目的に応じて適宜選択すればよい。In preparing a composition to be dissolved and taken in the mouth, the excipients and other additives to be added to the coated particles obtained according to the present invention are usually those in the field of dietary supplements and pharmaceuticals. Any known products known to be used when producing troches, chewables, and the like to be dissolved in the mouth may be used as appropriate. Examples of the additive include a non-aqueous binder, a disintegrant, a sweetener, a flavor, a preservative, and the like. The composition to be dissolved in the mouth may be produced in accordance with a conventionally known method for producing a troche or chewable. Briefly, excipients and other additives may be mixed with the coated particles of the present invention and compressed with a suitable tableting device. The shape and physical properties of the tablet are not particularly limited, and may be appropriately selected according to the purpose.
【0027】本発明により得られる組成物は、従来問題
となっていた酵母エキスの不快な味や臭いが十分マスキ
ングされている。従って本発明により、グルタチオンを
口中で溶解させ、舌下から吸収できる製剤として提供す
ることができるようになった。The composition obtained according to the present invention is sufficiently masked with the unpleasant taste and odor of the yeast extract, which has conventionally been a problem. Therefore, according to the present invention, glutathione can be dissolved in the mouth and provided as a preparation that can be absorbed under the tongue.
【0028】以下、実施例により本発明を更に詳細に説
明する。Hereinafter, the present invention will be described in more detail with reference to examples.
【実施例1】トルラ酵母エキス(グルタチオン含有酵母
エキス)YH1((株)興人より購入)を用いて、組成
物の製造条件を検討した。使用した酵母エキス粉末は、
グルタチオンを8.9重量%含有するものであった。酵
母エキス末6000gとショ糖脂肪酸エステル180g
を混合機へ投入し、3分間混合した。得られた混合粉末
をLibbra836KAWCZ型打錠機(菊水製作
所)にて、10.5mm扁平Rの杵を用い、1錠の重量
を300mgに設定し、打錠圧力を500〜3000k
g/cm2の間で変化させて固形化物を得た。得られた
固形化物の硬度を調べた。結果を表1に示す。Example 1 The production conditions of the composition were examined using Torula yeast extract (a glutathione-containing yeast extract) YH1 (purchased from Kojin Co., Ltd.). The yeast extract powder used was
It contained 8.9% by weight of glutathione. 6000 g yeast extract powder and 180 g sucrose fatty acid ester
Was charged into a mixer and mixed for 3 minutes. Using a 10.5 mm flat R punch, the weight of one tablet was set to 300 mg and the tableting pressure was set to 500 to 3000 k using a Libra 836 KAWCZ type tableting machine (Kikusui Seisakusho).
g / cm 2 to obtain a solid. The hardness of the obtained solid was examined. Table 1 shows the results.
【0029】[0029]
【表1】 [Table 1]
【0030】表1に示した固形化物のうち、AおよびB
には割れ、欠けが見られたため、次の段階には用いなか
った。得られたC〜Hの各錠剤を、粉砕および分級し
た。粉砕にはロール式粉砕器RC212(菊水製作所)
を用いた。粉砕した後、得られた粒子を篩にかけ、分級
した。分級は自動篩器(晃栄産業)を用いた。分級は粒
子がそれぞれ10〜14、14〜24、24〜50、5
0〜80、80〜100および100〜200メッシュ
の粒子に分けた。Of the solids shown in Table 1, A and B
Was not used for the next stage because cracking and chipping were observed. Each of the obtained C to H tablets was pulverized and classified. Roll type crusher RC212 (Kikusui Seisakusho) for crushing
Was used. After pulverization, the obtained particles were sieved and classified. Classification was performed using an automatic sieve (Koei Sangyo). Classification is performed when particles are 10 to 14, 14 to 24, 24 to 50, and 5 respectively.
It was divided into particles of 0-80, 80-100 and 100-200 mesh.
【0031】得られた各粒径の粒子を、精製シェラック
5000gをエタノール10000gと混合し、2時間
ボールミルで混合して得たシェラックのエタノール溶液
にて被覆した。被覆は、糖衣パン603型(イワクロ製
作所)を用い、ここへ分級した粉砕粒子を投入した。粉
砕粒子重量に対して26重量%のシェラックのアルコー
ル溶液を噴霧し、被覆処理を行った。次いで、糖衣パン
中へタルク粉末を添加し被覆した。べたついた表面が均
等に皮膜された時点で、粉砕粒子に対して24.27重
量%のタルクが使用されていた。The obtained particles having the respective particle diameters were coated with an ethanol solution of shellac obtained by mixing 5000 g of purified shellac with 10,000 g of ethanol and mixing for 2 hours with a ball mill. For coating, sugar-coated bread type 603 (Iwakuro Seisakusho) was used, and the classified crushed particles were added thereto. A coating treatment was performed by spraying a shellac alcohol solution of 26% by weight based on the weight of the pulverized particles. Next, talc powder was added to the sugar-coated bread and coated. At the point when the sticky surface was evenly coated, 24.27% by weight of talc was used based on the ground particles.
【0032】被覆後、一旦粒子を取り出し、38℃にて
24時間乾燥させた後、上記と同様にして再度シェラッ
クのエタノール溶液およびタルクによる仕上げ被覆を行
った。この仕上げ被覆では、粉砕粒子の重量に対して7
重量%のシェラックのエタノール溶液を噴霧し、次いで
タルクを添加してさらに皮膜を形成させた。タルクによ
り均等に皮膜され、臭いが薄れた時点でのタルクの使用
量は粉砕粒子に対して6.12重量%であった。被覆処
理終了後、38℃にて24時間乾燥させ被覆粒子を得
た。After the coating, the particles were once taken out, dried at 38 ° C. for 24 hours, and again subjected to a finish coating with an ethanol solution of shellac and talc in the same manner as described above. In this finish coating, 7
A weight percent solution of shellac in ethanol was sprayed on and then talc was added to further form a film. The amount of talc used was 6.12% by weight based on the ground particles when the film was uniformly coated with talc and the odor was reduced. After the completion of the coating treatment, the coating was dried at 38 ° C. for 24 hours to obtain coated particles.
【0033】得られた被覆粒子を用い、口中で溶かして
服用するための錠剤を作成した。以下の成分: 被覆粒子 8908g ビタミンC 4044g 還元麦芽糖 3600g リボフラビン 8g からなる混合物をV型混合機VM−200(不二パウダ
ル)にて混合し、次いでティンドームグランTDG−1
10(不二パウダル)にて造粒し、38℃にて乾燥し
た。Using the obtained coated particles, tablets were prepared for dissolution in the mouth and for taking. The following components: coated particles 8908 g Vitamin C 4044 g Reduced maltose 3600 g Riboflavin 8 g is mixed in a V-type mixer VM-200 (Fuji Paudal), and then Tindome Gran TDG-1
The mixture was granulated at 10 (Fuji Paudal) and dried at 38 ° C.
【0034】得られた造粒物へさらにオレンジミクロン
(香料)540gおよびショ糖脂肪酸エステル(滑沢
剤)900gを添加して、V型混合機VM−200(不
二パウダル)にて混合した。得られた混合物を、コレク
ト21Kr(菊水製作所)を用いて打錠した。打錠は以
下の条件で行った: 使用杵:16mm扁平R 錠剤重量:1800mg 打錠圧力:850〜1000kg 錠剤硬度:5〜8kg 打錠後、タブレットクリーナーCTC−502(日本グ
ラニュレーター)にて錠剤表面をクリーニングして、実
施例1の錠剤を得た。得られた錠剤はそれぞれ、直径1
6mm厚み約6mm、錠剤重量約1800mgの、淡黄
色直径16mmの平型トローチ剤である。得られた錠剤
を口中に含み、その味および臭いにより、口中で溶解さ
せて服用することが可能であるか否かを評価した。結果
を表2に示す。Further, 540 g of orange micron (perfume) and 900 g of sucrose fatty acid ester (lubricant) were added to the obtained granules, and mixed with a V-type mixer VM-200 (Fuji Paudal). The resulting mixture was tableted using Collect 21Kr (Kikusui Seisakusho). Tableting was carried out under the following conditions: punch used: 16 mm flat R tablet weight: 1800 mg tableting pressure: 850 to 1000 kg tablet hardness: 5 to 8 kg The surface was cleaned to obtain the tablet of Example 1. Each of the obtained tablets has a diameter of 1
It is a flat lozenge with a pale yellow diameter of 16 mm and a thickness of about 6 mm and a tablet weight of about 1800 mg. The obtained tablet was contained in the mouth, and it was evaluated whether or not the tablet could be dissolved in the mouth and taken based on the taste and smell. Table 2 shows the results.
【0035】[0035]
【表2】 [Table 2]
【0036】被覆処理前の粒子の粒径が24〜80メッ
シュのもののみ、口中で溶解させて服用することの可能
な味および臭いであった。しかしながらこの粒径であっ
ても、破砕処理前の固形化物の硬度が8.5kg以下の
場合には、硬度が不十分のため、処理工程で溶解した。Only particles having a particle size of 24-80 mesh before coating had a taste and odor that could be dissolved in the mouth and taken. However, even with this particle size, if the hardness of the solidified product before the crushing treatment was 8.5 kg or less, the solidified product was dissolved in the treatment step due to insufficient hardness.
【0037】[0037]
【実施例2】実施例1に用いたものと同じ成分および装
置を用い、酵母エキス粉末の圧縮成形時の圧力を110
0kg/cm2として固形化物を作成し、これを粉砕し
て24〜80メッシュの粒子へ分級した。Example 2 Using the same components and equipment as used in Example 1, the pressure during the compression molding of the yeast extract powder was set to 110
A solidified product was prepared at 0 kg / cm 2 , which was pulverized and classified into 24-80 mesh particles.
【0038】得られた粒子を実施例1と同じ糖衣パン内
へ投入し、下地被覆として、実施例1と同じ精製シェラ
ックのエタノール溶液を実施例1と同じ量噴霧して被覆
し、次いで糖衣パンへ牡蠣殻粉末を735g加えた後、
さらにタルクを735g加えて被覆させた。得られた粒
子を38℃で24時間乾燥させ、次いで仕上げ被覆とし
て、実施例1と同じ量のシェラックのエタノール溶液で
被覆処理した後、牡蠣殻粉末245g、さらにタルク2
45gを糖衣パンに投入し、被覆させた。得られた被覆
粒子を38℃で24時間乾燥させて、次の段階へ用い
た。The obtained particles were put in the same sugar-coated bread as in Example 1, and the same amount of purified shellac as in Example 1 was sprayed with the same amount of ethanol solution as in Example 1 and coated as a base coat. After adding 735 g of oyster shell powder,
Further, 735 g of talc was added for coating. The obtained particles were dried at 38 ° C. for 24 hours and then coated with the same amount of a shellac ethanol solution as in Example 1 as a final coating, followed by 245 g of oyster shell powder and talc 2
45 g were put into sugar-coated bread and coated. The resulting coated particles were dried at 38 ° C. for 24 hours and used for the next step.
【0039】得られた被覆粒子を、以下の処方で実施例
1と同様にして成形して実施例2の錠剤を得た。 処方: 被覆粒子 8656g ビタミンC 3930g 還元麦芽糖 3500g リボフラビン 7g 香料 522g ショ糖脂肪酸エステル 875g 合計 17490g 仕上がり 17490gThe obtained coated particles were molded in the same manner as in Example 1 with the following formulation to obtain a tablet of Example 2. Formulation: coated particles 8656 g vitamin C 3930 g reduced maltose 3500 g riboflavin 7 g fragrance 522 g sucrose fatty acid ester 875 g Total 17490 g Finish 17490 g
【0040】得られた錠剤中のグルタチオン量を測定し
た。なお、錠剤1錠あたりの各成分の配合量は以下の通
りである:The amount of glutathione in the obtained tablets was measured. In addition, the compounding quantity of each component per tablet is as follows:
【表3】 [Table 3]
【0041】グルタチオン量は、常法により測定した。
酵母エキス粉末中、グルタチオン含量が8.9%である
ことから、理論値としては600mg×8.9%=53.
4mgであるが、最終製品中の実測値は50.7mgで
あった。The amount of glutathione was measured by a conventional method.
Since the glutathione content in the yeast extract powder is 8.9%, the theoretical value is 600 mg × 8.9% = 53.
4 mg, but the found in the final product was 50.7 mg.
【0042】[0042]
【実施例3】実施例2で製造した錠剤(A)および比較
例として、表4に記載の材料:Example 3 The tablet (A) produced in Example 2 and the materials listed in Table 4 as comparative examples:
【表4】 [Table 4]
【0043】を、混合し、実施例1と同様にして打錠し
て得た錠剤(B)を製造した。26名の被験者、男性11
名(20〜55歳)、女性15名(22〜50歳)がそ
れぞれの錠剤を口中に含み、なめた。口中に含み得た期
間、味、および臭いについて評価した。Were mixed and tableted in the same manner as in Example 1 to produce a tablet (B). 26 subjects, 11 men
Names (20-55 years old) and 15 women (22-50 years old) licked each tablet in their mouth. The duration, taste and odor that could be included in the mouth were evaluated.
【0044】この試験の結果、被験者全員が本発明の錠
剤(A)については、錠剤が口中で完全に溶解するまで
なめることができ、美味であり、臭いは気にならないと
評価した。一方、酵母エキス粉末を賦形剤等と共に圧縮
成形した錠剤(B)については、被験者全員が口に入れ
たとたんに我慢できなくなるほど不味く、また臭いにつ
いても耐えがたいものであると評価した。As a result of this test, all the subjects evaluated that the tablet (A) of the present invention could be licked until the tablet was completely dissolved in the mouth, tasted good, and odor was not noticeable. On the other hand, the tablet (B) obtained by compression-molding the yeast extract powder together with excipients and the like was evaluated as unsatisfactory enough that all the test subjects could not stand it as soon as they were put into their mouths, and also unsatisfactory with regard to odor.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 47/02 A61K 47/04 47/04 47/30 47/30 47/38 47/38 A61P 1/16 // A61P 1/16 3/06 3/06 37/08 37/08 39/02 39/02 A61K 37/02 Fターム(参考) 4B018 LE01 LE02 MD01 MD03 MD04 MD20 MD34 MD35 MD81 ME14 MF01 MF07 MF08 4C076 AA44 BB01 DD21H DD25H DD27H DD28H DD29H EE30H EE31H EE32H EE58H FF06 FF52 FF68 GG16 4C084 AA03 BA15 CA05 MA05 MA35 MA52 NA09 ZA711 ZA712 ZA751 ZA752 ZB131 ZB132 ZC331 ZC332 ZC371 ZC372 4C087 AA01 BC11 MA05 MA35 MA52 NA09 ZA71 ZA75 ZB13 ZC33 ZC37 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 47/02 A61K 47/04 47/04 47/30 47/30 47/38 47/38 A61P 1/16 // A61P 1/16 3/06 3/06 37/08 37/08 39/02 39/02 A61K 37/02 F term (reference) 4B018 LE01 LE02 MD01 MD03 MD04 MD20 MD34 MD35 MD81 ME14 MF01 MF07 MF08 4C076 AA44 BB01 DD21H DD25H DD27H DD28H DD29H EE30H EE31H EE32H EE58H FF06 FF52 FF68 GG16 4C084 AA03 BA15 CA05 MA05 MA35 MA52 NA09 ZA711 ZA712 ZA751 ZA752 ZB131 ZB132 ZC331 ZC332 ZC371 ZC3724A037C
Claims (8)
を無水条件下で圧縮成形により固形化物を得る工程、得
られた固形化物を破砕して造粒する工程、破砕により得
られた粒子を、非水性コーティング剤で被覆する工程を
含む、グルタチオン含有酵母エキスを含む組成物の製造
方法。1. A step of obtaining a solidified product by compression-molding a yeast extract powder containing glutathione under anhydrous conditions, a step of crushing and granulating the obtained solidified product, A method for producing a composition containing a glutathione-containing yeast extract, comprising a step of coating with a coating agent.
上であり、破砕により得られる粒子の平均粒径が24〜
80メッシュである、請求項1記載の方法。2. The solidified product has a hardness of 10 kg / cm 2 or more, and the particles obtained by crushing have an average particle size of 24 to
The method of claim 1, wherein the method is 80 mesh.
ヒドロキシエチルセルロース、ヒドロキシエチルデンプ
ン、ヒドロキシプロピルセルロース、およびヘミロース
からなる群から選択される物質のアルコール溶液、およ
び、タルク、牡蠣殻を含むボレイ、酸化亜鉛、酸化アル
ミウム、酸化カルシウム、酸化チタン、酸化プロピレ
ン、酸化マグネシウム、炭酸カリウム、炭酸カルシウ
ム、炭酸水素ナトリウム、炭酸ナトリウム、炭酸マグネ
シウム、炭酸リチウム、沈降炭酸カルシウムおよび天然
ケイ酸アルミニウムからなる群より選択される粉末から
なる、請求項1または2記載の方法。3. The non-aqueous coating agent comprises shellac,
Alcohol solution of a substance selected from the group consisting of hydroxyethylcellulose, hydroxyethylstarch, hydroxypropylcellulose, and hemylose, and talc, oyster hulls, zinc oxide, aluminum oxide, calcium oxide, titanium oxide, propylene oxide, The method according to claim 1 or 2, comprising a powder selected from the group consisting of magnesium oxide, potassium carbonate, calcium carbonate, sodium bicarbonate, sodium carbonate, magnesium carbonate, lithium carbonate, precipitated calcium carbonate and natural aluminum silicate.
ルコール溶液および、タルクおよび/または牡蠣粉末を
含む、請求項3記載の方法。4. The method according to claim 3, wherein the non-aqueous coating comprises an alcoholic solution of shellac and talc and / or oyster powder.
他の添加剤と共に圧縮成形して、口中で溶解させて服用
するための製剤とする工程をさらに含む、請求項1記載
の方法。5. The method of claim 1, further comprising the step of compression molding the resulting coated particles with excipients and other additives to form a formulation for dissolution in the mouth for administration.
10%含有するものである、請求項1〜5いずれかに記
載の方法。6. The yeast extract powder contains glutathione 8 to
The method according to any one of claims 1 to 5, wherein the content is 10%.
条件下で圧縮成形により固形化物を得る、得られた固形
化物を破砕する、破砕により得られた粒子を、非水性コ
ーティング剤で被覆することによって得られる、グルタ
チオン含有酵母エキスを含む組成物。7. A glutathione-containing yeast extract powder is obtained by compression molding under anhydrous conditions to obtain a solidified product, crushing the obtained solidified product, and coating the particles obtained by the crushing with a non-aqueous coating agent. A composition comprising a glutathione-containing yeast extract.
ある、請求項7記載の組成物。8. The composition according to claim 7, which is intended to be dissolved in the mouth and taken.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000283502A JP2002097153A (en) | 2000-09-19 | 2000-09-19 | Composition containing glutathione-containing yeast extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000283502A JP2002097153A (en) | 2000-09-19 | 2000-09-19 | Composition containing glutathione-containing yeast extract |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002097153A true JP2002097153A (en) | 2002-04-02 |
Family
ID=18767857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000283502A Pending JP2002097153A (en) | 2000-09-19 | 2000-09-19 | Composition containing glutathione-containing yeast extract |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2002097153A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103393097A (en) * | 2013-08-02 | 2013-11-20 | 永安康健药业(武汉)有限公司 | Health food with effects of sobering and protecting liver |
US8859807B2 (en) | 2006-10-04 | 2014-10-14 | Kyowa Hakko Bio Co., Ltd. | Glutathione preparation and method for production thereof |
US9918951B2 (en) | 2008-02-05 | 2018-03-20 | Kyowa Hakko Bio Co., Ltd. | Method for improving storage stability of glutathione |
JP2019131517A (en) * | 2018-02-01 | 2019-08-08 | エスエス製薬株式会社 | Oral solution |
JP2023182650A (en) * | 2018-02-21 | 2023-12-26 | 日本新薬株式会社 | Granular composition, method for producing granular composition, and method for improving dissolution of granular composition |
-
2000
- 2000-09-19 JP JP2000283502A patent/JP2002097153A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859807B2 (en) | 2006-10-04 | 2014-10-14 | Kyowa Hakko Bio Co., Ltd. | Glutathione preparation and method for production thereof |
US9918951B2 (en) | 2008-02-05 | 2018-03-20 | Kyowa Hakko Bio Co., Ltd. | Method for improving storage stability of glutathione |
CN103393097A (en) * | 2013-08-02 | 2013-11-20 | 永安康健药业(武汉)有限公司 | Health food with effects of sobering and protecting liver |
JP2019131517A (en) * | 2018-02-01 | 2019-08-08 | エスエス製薬株式会社 | Oral solution |
JP7057150B2 (en) | 2018-02-01 | 2022-04-19 | エスエス製薬株式会社 | Oral liquid |
JP2023182650A (en) * | 2018-02-21 | 2023-12-26 | 日本新薬株式会社 | Granular composition, method for producing granular composition, and method for improving dissolution of granular composition |
JP7639092B2 (en) | 2018-02-21 | 2025-03-04 | 日本新薬株式会社 | Granular composition, method for producing granular composition, and method for improving dissolution property of granular composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6358526B1 (en) | Method of making tablets and tablet compositions produced therefrom | |
JP2688614B2 (en) | Spray dried ibuprofen | |
CA2618977C (en) | Orally disintegratable tablet | |
JP6086798B2 (en) | Tablet manufacturing method | |
JP2002529496A (en) | Preparation method of oral calcium composition | |
JP5004236B2 (en) | Orally disintegrating tablets | |
CN1327838C (en) | Vitamin C oral disintegration tablet and its preparing method | |
JP2016174616A (en) | Disintegrable composition, and easily disintegrable compression molding | |
CN104524541B (en) | A kind of jellyfish albumen effervescent tablet and preparation method thereof | |
JP2002097153A (en) | Composition containing glutathione-containing yeast extract | |
JP4565219B2 (en) | Polyphenol-containing granule or polyphenol-containing chewable tablet and method for producing the same | |
CN102258490B (en) | Ibuprofen chewable tablet | |
JPS648605B2 (en) | ||
JP2002029964A (en) | Solid medicine composition | |
JP3341768B1 (en) | Chewable preparation containing branched-chain amino acids | |
JP2007332074A (en) | Tablet quickly disintegrable in oral cavity and method for producing the same | |
JP2003063951A (en) | Tablet and method for producing the same | |
JP2000044463A (en) | Rapidly dissolvable tablet | |
JP6004702B2 (en) | Method for producing solid preparation with reduced unpleasant taste | |
JP3778240B2 (en) | Granulated composition masked by unpleasant taste and method for producing the same | |
JP2002138055A (en) | Intraoral quick disintegration type compression molding and its production method | |
BE1030890B1 (en) | A DIETARY SUPPLEMENT AIMED AT STRENGTHENING IMMUNITY TO PREVENT RESPIRATORY SYSTEM INFECTIONS AND ITS PREPARATION PROCESS | |
JP2006335686A (en) | Method for producing erythritol-sorbitol mixed granule for direct tableting | |
EP2826464A1 (en) | Sustained release solid dosage preparations | |
JP2025005430A (en) | Oral Compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040720 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050118 |